In the neoadjuvant setting, the use of a trastuzumab‐based regimen for HER2+ breast cancer has resulted in a high pathologic complete response (pCR) rate, which indicates a good patient prognosis.3, 4, 5. This evidence concerns the gene ERBB2 and breast cancer.